Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock [Yahoo! Finance]
Ascendis Pharma A/S - Ordinary Share (ASND)
Last ascendis pharma a/s - ordinary share earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
The primary catalyst for hedge fund interest in Ascendis Pharma A/S (NASDAQ:ASND) stock over the past few weeks is the FDA approval of YUVIWEL for children with achondroplasia. Earlier this month, Ascendis received Orphan Drug Exclusivity and officially launched YUVIWEL in the United States. YUVIWEL is a major competitor to BioMarin's Voxzogo. Analysts note that YUVIWEL's once-weekly dosing schedule offers a significant lifestyle advantage over daily injectables, which is expected to drive market share gains. The firm recently completed its transition from American Depositary Shares (ADSs) to a direct listing of ordinary shares on the Nasdaq. This structural change was designed specifically to broaden access to global investors. Citigroup Inc. (C): Among Incredibly Cheap Dividend Stock to Buy Now Top investors are buying Ascendis Pharma A/S (NASDAQ:ASND) stock ahead of potential inclusion in major equity indexes like the Russell 1000 or specialized biotech indexes. Direct listing
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - Ordinary Share news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028GlobeNewswire
- Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqGlobeNewswire
- Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.MarketBeat
- Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.MarketBeat
- Ascendis Pharma to List Ordinary Shares Directly on NasdaqGlobeNewswire
ASND
Earnings
- 2/11/26 - Miss
ASND
Sec Filings
- 4/21/26 - Form 6-K
- 4/21/26 - Form 6-K
- 4/20/26 - Form 8-A12B/A
- ASND's page on the SEC website